Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04147650 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
A Phase 2 study, sponsored by Aurinia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 508
- Enrollment target
NCT04147650: Completed Phase 2 study, sponsored by Aurinia Pharmaceuticals.
NCT04147650 is a Phase 2 study that has completed, run by Aurinia Pharmaceuticals. The registered enrollment target is 508 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (282% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04147650, a Phase 2 study, has completed, sponsored by Aurinia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 508 participants
- Enrollment target
Study Summary
A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%, 0.10%, 0.20%) Compared to Vehicle in Subjects with Dry Eye Syndrome.
Primary Outcome
Number of subjects with a ≥10 mm increase from baseline in STT at Week 4 in the study eye. The STT scale is a measure of tear production with a minimum of 0 mm and no there is no specified maximum for this scale.
Interventions
- DRUG Vehicle Ophthalmic Solution
- DRUG 0.05% Voclosporin Ophthalmic Solution (VOS)
- DRUG 0.10% VOS
- DRUG 0.20% VOS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2020-10-08 |
| Phase | Phase 2 |
What the finished NCT04147650 record still lists
NCT04147650 is an interventional study that assigns participants to a tested intervention. The registered 508 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (282% higher).
The record links to 0 conditions, and to 4 interventions - of which Vehicle Ophthalmic Solution is the first listed.
NCT04147650 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04147650 about?
NCT04147650 is a clinical study titled "Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome". A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%, 0.10%, 0.20%) Compared to Vehicle in Subjects with Dry Eye Syndrome.
What is the current status of trial NCT04147650?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 508 participants. The study started on 2019-10-14. Estimated completion is 2020-10-08.
What interventions are being tested in trial NCT04147650?
The interventions under investigation include: Vehicle Ophthalmic Solution (DRUG), 0.05% Voclosporin Ophthalmic Solution (VOS) (DRUG), 0.10% VOS (DRUG), 0.20% VOS (DRUG).
Who is sponsoring clinical trial NCT04147650?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04147650's enrollment target sits among peer trials
508 69th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- NCT07484217 · 508 participants · Phase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI